Page 141 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 141
Cirrhosis and its Complications: Clinical Aspects
P0118 PHASE 1-2 CLINICAL TRIAL IN PATIENTS WITH
DECOMPENSATED LIVER CIRRHOSIS TREATED WITH
BONE-MARROW DERIVED ENDOTELIAL PROGENITOR
CELLS
Delia D’Avola*, Veronica Fernandez-Ruiz,
Francisco Carmona de la Torre, Miriam Mendez, Felipe Prosper,
Enrique Andreu, Jose Ignacio Herrero, Mercedes Iñarrairaegui,
Carmen Fuertes, Bruno Sangro, Jesus Prieto, José Ignacio Bilbao,
Jorge Quiroga, Spain
P0119 VALIDATION OF THE NACSELD INFECTION-RELATED
ACUTE-ON-CHRONIC LIVER FAILURE (I-ACLF) SCORE IN
AN INDEPENDENT MULTICENTER COHORT
Jacqueline G. O’leary*, K. R. Reddy, Guadalupe Garcia-Tsao,
Scott W. Biggins, Florence Wong, Michael B. Fallon, Ram Subramanian,
Patrick S. Kamath, Paul Thuluvath, Benedict Maliakkal, Heather Patton,
Puneeta Tandon, Leroy R. Thacker, Jasmohan S. Bajaj, The United States
P0120 THE 3-MONTH READMISSION RATE REMAINS
UNACCEPTABLY HIGH IN A LARGE MULTI-CENTER
COHORT OF CIRRHOTIC PATIENTS ePOSTERS
Jasmohan S. Bajaj*, K R. Reddy, Guadalupe Garcia-Tsao,
Florence Wong, Michael B. Fallon, Ram Subramanian, Scott W. Biggins,
Benedict Maliakkal, Patrick S. Kamath, Paul Thuluvath,
Leroy R. Thacker, Jacqueline G. O’leary, The United States
P0121 ANGIOTENSIN II INHIBITION TO TREAT SEVERE LIVER
FIBROSIS: A DOUBLE-BLIND RANDOMIZED TRIAL (ANRS
HC19)
Paul Cales*,Yannick Bacq, Corinne Bonny, Jean Louis Payen,
Dominique Guyader, Albert Tran, Dominique Larrey, Christine Silvain,
Marie Christine Rousselet, Mélanie Simony, Frédéric Oberti,
Fabrice Carrat, France
P0122 TYPE 2 DIABETES REDUCES OVERALL SURVIVAL AND
INCREASES THE RISK OF HEPATIC DECOMPENSATION
IN HCV-RELATED LIVER CIRRHOSIS. RESULTS FROM A
PROSPECTIVE LONG-TERM STUDY DURING 8 YEARS
Eduardo Vilar-Gomez*, Luis Calzadilla Bertot, Ali Yasells Garcia,
Yadina Martinez Perez, Manuel Romero-Gomez, Moises Diago, Cuba,
Spain
Vienna, Austria • April 22–26, 2015 141
P0118 PHASE 1-2 CLINICAL TRIAL IN PATIENTS WITH
DECOMPENSATED LIVER CIRRHOSIS TREATED WITH
BONE-MARROW DERIVED ENDOTELIAL PROGENITOR
CELLS
Delia D’Avola*, Veronica Fernandez-Ruiz,
Francisco Carmona de la Torre, Miriam Mendez, Felipe Prosper,
Enrique Andreu, Jose Ignacio Herrero, Mercedes Iñarrairaegui,
Carmen Fuertes, Bruno Sangro, Jesus Prieto, José Ignacio Bilbao,
Jorge Quiroga, Spain
P0119 VALIDATION OF THE NACSELD INFECTION-RELATED
ACUTE-ON-CHRONIC LIVER FAILURE (I-ACLF) SCORE IN
AN INDEPENDENT MULTICENTER COHORT
Jacqueline G. O’leary*, K. R. Reddy, Guadalupe Garcia-Tsao,
Scott W. Biggins, Florence Wong, Michael B. Fallon, Ram Subramanian,
Patrick S. Kamath, Paul Thuluvath, Benedict Maliakkal, Heather Patton,
Puneeta Tandon, Leroy R. Thacker, Jasmohan S. Bajaj, The United States
P0120 THE 3-MONTH READMISSION RATE REMAINS
UNACCEPTABLY HIGH IN A LARGE MULTI-CENTER
COHORT OF CIRRHOTIC PATIENTS ePOSTERS
Jasmohan S. Bajaj*, K R. Reddy, Guadalupe Garcia-Tsao,
Florence Wong, Michael B. Fallon, Ram Subramanian, Scott W. Biggins,
Benedict Maliakkal, Patrick S. Kamath, Paul Thuluvath,
Leroy R. Thacker, Jacqueline G. O’leary, The United States
P0121 ANGIOTENSIN II INHIBITION TO TREAT SEVERE LIVER
FIBROSIS: A DOUBLE-BLIND RANDOMIZED TRIAL (ANRS
HC19)
Paul Cales*,Yannick Bacq, Corinne Bonny, Jean Louis Payen,
Dominique Guyader, Albert Tran, Dominique Larrey, Christine Silvain,
Marie Christine Rousselet, Mélanie Simony, Frédéric Oberti,
Fabrice Carrat, France
P0122 TYPE 2 DIABETES REDUCES OVERALL SURVIVAL AND
INCREASES THE RISK OF HEPATIC DECOMPENSATION
IN HCV-RELATED LIVER CIRRHOSIS. RESULTS FROM A
PROSPECTIVE LONG-TERM STUDY DURING 8 YEARS
Eduardo Vilar-Gomez*, Luis Calzadilla Bertot, Ali Yasells Garcia,
Yadina Martinez Perez, Manuel Romero-Gomez, Moises Diago, Cuba,
Spain
Vienna, Austria • April 22–26, 2015 141
